Benzinga | Aug 4, 2020 05:21PM EDT

Recap: GenMark Diagnostics Q2 Earnings

Shares of GenMark Diagnostics (NASDAQ:GNMK) moved lower by 6.81% in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share were up 69.57% over the past year to ($0.07), which beat the estimate of ($0.09).

Revenue of $40,086,000 rose by 118.17% from the same period last year, which beat the estimate of $32,740,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

GenMark Diagnostics hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Aug 04, 2020

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/z6k7ozmw

Price Action

52-week high: $19.83

Company's 52-week low was at $3.36

Price action over last quarter: Up 71.87%

Company Profile

GenMark Diagnostics Inc is a provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. The company currently operates in one reportable business segment, which encompasses the development, manufacturing, sales, and support of instruments and molecular tests based on its proprietary eSensor detection technology. Its operations and assets are in the United States of America.